| bibliographicCitation |
Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho C, Cardozo N, Maia B, Khan T, Singh Y, Middelkoop K, Franks J, Valencia J, Sanchez N, Lucas J, Rooney JF, Rinehart AR, Ford S, Adeyeye A, Cohen MS, McCauley M, Landovitz RJ, Grinsztejn B, Chariyalertsak S, Ungsedhapand C, Phanuphak N, Ha TV, Figueroa MI, Losso MH, Kallas EG, Valdez Madruga J, Riegel Santos B, Grinsztejn B, Boyer JCH, Aguirre MEM, Gallardo-Cartagena JA, Valencia J, Ramirez YP, Middelkoop K, Goepfert P, Hosek S, Liu A, Justman J, Hurt C, Reirden D, Fichtenbaum C, Hall C, Mayer K, Magnus M, van Dam C, Franks J, Kelley C, Arduino RC, Rompalo A, Swaminathan S, Abdalian SE, Van Tieu H, Bazan J, Frank I, del Rio C, Gaur A, Landovitz RJ, Clark J, Novak R, Presti R, Gulick R(. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. The Lancet HIV. 2023 Nov;10(11):e703–12. doi: 10.1016/s2352-3018(23)00200-x. |